Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Side Effect Risk Could Be Preventing Stroke Patients from Taking Statins



Once a person suffers a stroke, they are at risk of a recurrence, which also increases their odds of mortality.

Share this!

July 17, 2017 | by Sarah Hand, M.Sc.

Researchers in the UK have found that stroke survivors may not be taking their statin medicines as prescribed over concerns about potential side effects associated with the drugs. According to patients’ own reports about why they stopped taking the cholesterol-lowering drugs, recent media coverage highlighting the side effects – including increased risk of developing diabetes and liver damage – exacerbated the medication adherence issue.

Once a person suffers a stroke, they are at risk of a recurrence, which also increases their odds of mortality. To mitigate this risk, stroke survivors are often prescribed statins and other preventative medications, however about one third of patients don’t follow their prescribed medication schedule.

By analyzing posts on the Stoke Association’s forum TalkStroke, researchers at the University of Cambridge and Queen Mary University, London (QMUL) sought to determine what reasons patients and their caregivers had for not taking their post-stroke medications as prescribed. The study spanned a seven-year period, from 2004 to 2011, with both patients who had a stroke and their caregivers posting on the site.

The researchers used a number of keywords – including ‘taking medication,’ ‘pills,’ and ‘side-effects’ – to find relevant posts for this medication adherence study. In all, they identified 84 posts submitted by participants, including 49 from stroke patients and 33 from their caregivers. The researchers published their analysis of those posts in the journal, BMJ Open.

The UK team found that side effects of medications were cited as one of the main contributors to a stroke survivor’s decision to stop taking the drugs. While some patients referred to the negative side effects they themselves experienced while taking statins, others made the decision to cease taking the drugs after reading about the potential side effects in the news.

“These findings have highlighted the need for an open, honest dialogue between patients and/or their carers, and healthcare professionals,” said senior study author Dr. Anna De Simoni, a lecturer in Primary Care Research at QMUL and visiting researcher at the Department of Public Health and Primary Care, University of Cambridge. “Doctors need to listen to these concerns, discuss the benefits and drawbacks of taking the medication, and be willing to support a patient's informed decision to refuse medications.”

Forum users also cited difficulties in swallowing large pills and complex drug regimens as reasons why they stopped taking their medication. The research highlights the importance of doctors’ willingness to work with patients to make medication adherence as convenient as possible for them.

“By analyzing people's views as expressed in online forums, where they are more open and less guarded, we've seen some valuable insights into why some stroke survivors have difficulty adhering to their medication,” said first author James Jamison, PhD candidate from the Department of Public Health and Primary Care at Cambridge. “Challenging negative beliefs about medication and adopting practices that make routines for taking medication simpler, particularly for those patients who have suffered disability as a result of stroke, should increase adherence and ultimately improve health outcomes.”

Keywords:  Stroke, Statin, Medication Adherence


Share this with your colleagues!

Researchers Identify Role of ApoE4 Gene as Possible Drug Target in Alzheimer’s Disease

September 21, 2017 - A team of neurology researchers at Washington University School of Medicine in St. Louis have found that in the presence of the ApoE4 protein, another protein known as tau forms tangles in the brain which contributes to neuronal damage characteristic of Alzheimer’s disease.

Featured In: Life Science News

New Guidelines Address CAR-T Immunotherapy Toxicities to Prevent Patient Deaths

September 20, 2017 - Clinicians at The University of Texas MD Anderson Cancer Center have published new guidelines in the journal, Nature Reviews Clinical Oncology, which could help in the management of these toxicities.

Featured In: Biotech News, Drug Safety News

Microneedle Skin Patch Could Treat Common Metabolic Disorders

September 19, 2017 - Researchers at Columbia University Medical Center (CUMC) and the University of North Carolina have developed a microneedle skin patch impregnated with a drug capable of converting white fat into calorie-burning brown fat.

Featured In: Medical Device News


Five Reasons Why Toronto is Emerging as a Major Life Sciences Hub


Development and Manufacture of Highly Potent API Drug Products Throughout the Clinical Phases

Innovation through Integration – Providing Next Generation Biomedical Devices and Interconnects

Clinical Payments Case Studies: Improving Efficiency, Cash Management, and Compliance

Why Phase 3 Trials Fail: Oncology Case Studies and Lessons Learned

Copyright © 2016-2017 Honeycomb Worldwide Inc.